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treatment failure. Adjuvant chemotherapy improves survival, but the 
absolute gain is modest and generally limited to stage II-IIIA. High-risk 
pts may be identiﬁed by gene expression proﬁles and considered for 
adjuvant chemotherapy. 
Methods: Of a consecutive series of 174 pts who underwent curative 
pulmonary resection between 2000 and 2004, we selected 66 stage I-
IIIA SqCLC pts (64 pts stage I and II and 2 pts stage IIIA): 33 pts who 
developed distant metastases and 33 who were free of distant relapse 
after a median follow-up of 37 months (range, 24-64 months). Snap 
frozen primary tumor specimens were obtained at the time of surgery. 
Sections were taken from blocks of tumor tissue for RNA extraction, 
and gene expression of 29 genes was assessed by RT-PCR using low 
density arrays. Expression values were dichotomized using the median 
as a cut-off value. 
Results: The univariate analysis identiﬁed 10 genes with signiﬁcant 
prognostic value: CSF1, EGFR, CA IX, PH4, KIAA0974, ANLN, 
VEGFC, NTRK1, FN1, INR1. In the multivariate Cox model, CSF1 
[HR=3.5, p=0.005], EGFR [HR=2.7, p=0.02], CA IX [HR=0.2, 
p<0.0001] and tumor size >4 cm [HR=2,7, p=0.02] emerged as 
signiﬁcant predictors of survival. A risk score based on the expres-
sion of CSF1, EGFR and CA IX was 70% accurate in predicting death 
risk. This model also performed well in predicting development of 
distant metastases, with 64% sensitivity and 73% speciﬁcity. A strong 
correlation was observed between some of these genes. For example, 
high levels of PH4 were related to low or no expression of CA IX (ρ = 
-0.33; p=0.007).
Conclusions: Overexpression of CSF1 and EGFR, and downregulation 
of CA IX was associated with particularly poor prognosis in SqCLC. 
Simultaneous assessment of the expression of these genes deﬁnes the 
group of SqCLC pts who might derive the highest beneﬁt from adju-
vant chemotherapy. 
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Background: Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (TKIs) are effective vs non-small cell lung cancer 
(NSCLC). Several known factors inﬂuence therapy efﬁcacy. 
Hypothesis: We hypothesized: 1) patient survival curves follow ﬁrst 
order kinetics. 2) Dichotomous (present vs absent) prognostic fac-
tors give inﬂection points on plots of log % cell survival vs time. 3) 
Nonlinear regression analysis of log-linear survival plots might permit 
identiﬁcation and characterization of prognostically distinct subgroups, 
and this could: a) aid in identiﬁcation of prognostic factors b) facilitate 
assessment of whether a therapy was having an impact on a distinct 
subpopulation or on the whole group.
Methods: Since much is already known about impact of EGFR TKIs 
in distinct NSCLC subgroups, we used published survival curves for 
EGFR TKI-treated patients to conduct preliminary assessments of this 
proposed methodology. We manually measured curve height from 215 
published survival or progression-free survival curves, replotted data 
as semilog plots, and performed compartmental nonlinear regression 
analyses using WinNonlin version 5.0.1 to assess number, size and 
half-life of identiﬁable distinct subgroups.
Results: Patterns identiﬁed were 1, 2, and 3 compartment curves, with 
2 compartment curves being most common. Some 1 compartment 
curves were convex, and some of these had a terminal plateau after the 
convexity, suggesting that they actually had a second compartment that 
had not been recognized by the analytical program due to the convex-
ity. Of 199 curves assessed in detail, 16 were 1 compartment without 
convexity, 11 were 1 compartment with convexity, 98 were 2 compart-
ment without convexity, 69 were 2 compartment with convexity in the 
ﬁrst portion, and 5 were 3 compartment. Analyses continue to assess 
whether we can identify speciﬁc treatment parameters or population 
factors that correlate with curve characteristics. 
Conclusions: When log % survival is plotted vs time, most survival 
curves have one or more inﬂection points suggesting distinct subpopu-
lations that differ by one or more dichotomous prognostic factors. 
These early analyses suggest that it is feasible to use compartmental 
nonlinear regression analysis to assess survival curves, although more 
complex modeling will be needed to optimally characterize curves 
with convex early portions. We plan to now use this methodology 
prospectively to link tumor and patient characteristics to prognostic 
subgroups. We will test the hypotheses that: 1) dichotomous variables 
account for curve inﬂection points. 2) The further to the right along 
the survival curve, the more homogeneous the remaining population 
for a phenotype conferring good prognosis. 3) Curve convexities are 
due to speciﬁc treatment practices (eg, discontinuing therapy after a set 
time period) or else are due to identiﬁable epigenetic events triggered 
early in therapy that lead to a maximum attainable survival time. 4) 
Assessment of therapies with respect to changes they induce in relative 
subgroup sizes and half-lives will help elucidate whether a treatment is 
affecting one patient subpopulation to a greater extent than another, and 
whether it is shifting patients from a poor prognosis group to a good 
prognosis group. Support: NCI Cancer Center Support Grant 5-P30 
CA16672 to UTMDACC. 
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Background: Pathologic stage of disease is the most important prog-
nostic factor in non-small cell lung cancer (NSCLC) patients treated 
by surgery. Nevertheless there is a great discrepancy in survival time 
observed within the groups with the same pathologic stage of disease.
The aim of the present study was to assess the prognostic role of pre-
treatment serum level of cytokeratin marker - Cyfra 21-1 and an acute 
phase protein - CRP in NSCLC patients (pts) treated by surgery. 
Methods: 39 pts, 30 men, 9 women, median age 62 (42-78) years, 
treated by surgery entered this study. Pathologic stage of disease was: 
Ia-IIb in 32 pts, IIIa in 4 pts, IIIb in 2 pts and IV in 1 pt ( single homo-
lateral lung metastasis ). Sera for Cyfra 21-1 (Elecsys Roche) and CRP 
(Roche/Hitachi) were obtained before surgery. 
Results: After 2 years of follow up 30 pts were still alive (pathologic 
stage Ia-IIb in 27, IIIa - in 2, and IIIb in 1 ). 9 pts were dead (pathologic 
stage Ia-IIb in 5, IIIa in 2, IIIb in 1 and IV in 1). Pretreatment serum 
CRP exceeded 10 mg/l in 7/9 pts who died and 14/30 pts who were 
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alive. Median serum CRP values were 23.5 (0.2-122.6) mg/l and 3.72 
(0.1-82.8) mg/l respectively (p=0.029). No correlation between CRP 
and pathologic stage of disease was found. Pretreatment Cyfra 21-1 
exceeded 3.3 ng/ml in 6/9 pts who died and 7/30 pts who were alive. 
Median Cyfra 21-1 concentrations were 5.29 (2.5-14.5) ng/ml and 1.92 
(0.7-6.2) respectively (p=0.0003). This difference was also signiﬁcant 
if only stage I and II pts were taken into analysis. 
Conclusion: Cyfra 21-1 and CRP are prognostic indicators in NSCLC 
patients treated by surgery and their inﬂuence on survival is probably 
partly independent from pathologic stage of disease. 
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Background: Intraoperative pleural lavage cytology (PLC) in patients 
with early stage of non-small cell lung cancer (NSCLCs) has been 
considered as possible aids to assess prognosis of lung cancers and was 
reported to be useful in detecting sub-clinical pleural dissemination, lo-
cal and systemic recurrence. Many studies revealed that only pre-opera-
tive PLC is necessary. We conduct a prospective study to explore any 
possible association of pre- and post-operative PCL and lymph node 
recurrence and the potential usefulness of post-operative PCL.
Methods: From December 2004 to December 2006, PLC was per-
formed before and after any manipulation or resection of the lung in 
24 consecutive patients, who had no macroscopic pleural effusion, 
dissemination, or diffuse adhesion, and who subsequently underwent 
curative resection for NSCLCs. The operations were performed by only 
one surgeon and the results of PLC with reference to clinicopathologic 
characteristics were evaluated and reported by only one pathologist. 
Tumor recurrence (local and systemic) was analyzed.
PLC consisted of cytological analysis of 50 mL of saline irrigated over 
the lung surface immediately after thoracotomy and after complete 
curative resection with radical mediastinal lymph node dissection.
Results: Nine (38%) of 24 patients had positive cytological ﬁndings. 
Positive cytological ﬁndings were observed more frequently in patients 
with adenocarcinoma, pleural involvement of the tumor and male 
gender.
Five (55%) of 9 patients had positive cytology in pre-operative PLC, 
3 (33%) in post-operative and 1 (11%) in both pre- and post-operative 
PLC. Exact McNemar signiﬁcance probability test showed no associa-
tion between pre- and post-operative cytological status (p= 0.727).
The risk of lymph nodes recurrence after 3 month of curative surgery 
in patients with negative and positive pre-operative PLC was 5.6% 
and 33.33% respectively (risk ratio = 6, 95%CI = 2 to 8, p = 0.143). In 
patients with both negative pre- and post-operative cytology, negative 
pre-operative but positive post-operative, positive pre-operative but 
negative post-operative, and positive both pre-and post-operative were 
6.7%, 0%, 20.0% and 100% respectively (p=0.123).
Conclusions: No relationship between cytological status of pleural 
lavage ﬂuid pre-operatively and post-operatively was detected. The 
study showed that if malignant cells were found in pre-operative PLC, 
the risk of lymph node recurrence in 3 months increased by 6 times, 
and maximum risk occurred when the malignant cells was found in 
both pre- and post-operative PLC. However, the increased risk was not 
statistically signiﬁcant because of the lack of statistical power due to 
small study size. If sample size were increased it may reveal that PLC 
may also be required at the time of curative resection for non-small cell 
lung cancer in order to estimate the risk of lymph node recurrence.
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Background: The primary aim of this trial was response. In both the 
control arm and in the genotypic arm with low tumor ERCC1 mRNA 
levels, p received docetaxel(doc)/cis; in the genotypic arm with high tu-
mor ERCC1 mRNA levels, p received doc/gemcitabine. Response was 
signiﬁcantly higher in the genotypic arms. We examined 324 p for ge-
netic markers that could inﬂuence response, including ERCC1 118 C/T, 
ERCC1 C8092A, XRCC3 241 (Thr to Met), Aurora A 91 T>A, Aurora 
A 169G>A, a SNP within intron 7 of the TGFBR1 gene (Int7G24A), 
and an in-frame germline deletion (TGFBR1*6A). Methylation of 14-
3-3 sigma and CHFR were also analyzed. 
Methods: DNA from peripheral lymphocytes was used for genotyp-
ing (Taqman assay) and methylation-speciﬁc PCR was used for 14-3-3 
sigma and CHFR in pretreatment serum DNA. 
Results: There were no differences in clinical characteristics among 
the different SNP types, except that p with Aurora A 91 AA had higher 
tumor ERCC1 mRNA levels (P=0.005). No relationship was found 
between ERCC1 SNPs and tumor ERCC1 mRNA levels. A strong 
correlation was found between the Int7G24A and XRCC3 241 SNPs 
(P=0.03). The Int7G24A GA type had a higher odds ratio (OR) of 
response (OR 2.32) than the AA type (OR 3.15) (P=0.02). XRCC3 241 
MetMet had a lower probability of response (OR 0.23) (P=0.04). No 
other differences in response were observed according to any of the 
other SNPs or methylation. In the multivariate model, the best response 
was observed in p with performance status (PS) 0, low ERCC1 levels, 
and XRCC3 241 SNP (Table). 
